1,25-Dihydroxyvitamin D3 Regulates Expression of Sex Steroid Receptors in Human Uterine Fibroid Cells
article
OA: bronze
CC0
⤵ 12 in-corpus citations
Abstract
CONTEXT: Uterine fibroids (UFs) are the most common benign tumors in premenopausal women. In this study, we evaluated the effects of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] for the treatment of UFs. OBJECTIVE: To determine the role of 1,25(OH)2D3 on the expression of sex steroid receptors in human UF cells. DESIGN: Human UFs and their adjacent myometrium were analyzed for expression of estrogen receptor (ER)-α, progesterone receptor (PR)-A, and PR-B, as well as members of the steroid receptor coactivator (SRC) family. Immortalized human uterine fibroid (human uterine leiomyoma [HuLM]) cells were treated with 1,25(OH)2D3 and assayed for the expression and localization of the aforementioned receptors and SRCs using Western blot, immunohistochemistry, immunofluorescence, and immunoprecipitation assays. MAIN OUTCOME MEASURES: We discovered a correlation between reduced levels of vitamin D receptor (VDR) and increased levels of ER-α, PR-A, and PR-B in these tissues. We evaluated the effects of 1,25(OH)2D3 on the regulation of the aforementioned sex steroid receptors. RESULTS: We observed an inverse correlation between the up-regulated ER-α, PR-A, and PR-B and expression of VDR in UFs. Treatment with 1,25(OH)2D3 significantly decreased levels of ER-α, PR-A, and PR-B, as well as SRCs in HuLM cells (P < .05). In contrast, 1,25(OH)2D3 self-induced its own VDR, which resulted in an induction of VDR-retinoid X receptor-α complex in HuLM cells. Together, these results suggest that 1,25(OH)2D3 functions as an antagonist of sex steroid hormone receptors in HuLM cells. CONCLUSIONS: 1,25(OH)2D3 functions as a potent antiestrogenic/antiprogesteronic agent that may have utility as a novel therapeutic option for UF.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (51)
- doi:10.1023/a:1005772432465 via openalex
- doi:10.1097/ede.0b013e31828acca0 via openalex
- doi:10.1210/endo.136.1.7530193 via openalex
- doi:10.1126/science.1112063 via openalex
- doi:10.1016/j.ogc.2005.12.001 via openalex
- doi:10.1016/s0083-6729(01)62006-5 via openalex
- doi:10.1016/s0002-9378(89)80046-8 via openalex
- doi:10.1097/01.ede.0000054360.61254.27 via openalex
- doi:10.1097/01.lab.0000017499.51216.3e via openalex
- doi:10.1016/j.mce.2011.05.020 via openalex
- doi:10.1016/j.ogc.2005.12.004 via openalex
- doi:10.1359/jbmr.1998.13.3.325 via openalex
- doi:10.1016/s1043-2760(02)00633-1 via openalex
- doi:10.1016/0002-9378(95)90077-2 via openalex
- doi:10.1016/j.fertnstert.2014.04.051 via openalex
- doi:10.1016/j.fertnstert.2014.06.050 via openalex
- doi:10.1093/ajcn/76.1.187 via openalex
- doi:10.1016/j.mce.2011.05.044 via openalex
- doi:10.1016/s0960-0760(00)00108-4 via openalex
- doi:10.1016/j.fertnstert.2010.07.1041 via openalex
- doi:10.1210/jcem.83.11.5287 via openalex
- W2159217959 via openalex
- W2406630756 via openalex
- W2628053793 via openalex
- doi:10.1095/biolreprod.111.098145 via openalex
- doi:10.1152/physrev.2001.81.4.1535 via openalex
- doi:10.3109/09513590.2011.569610 via openalex
- doi:10.1093/humupd/dmh019 via openalex
- doi:10.1016/0092-8674(95)90199-x via openalex
- doi:10.1210/me.2004-0390 via openalex
- doi:10.1093/humrep/12.4.815 via openalex
- doi:10.1056/nejmra1209993 via openalex
- doi:10.1210/jc.2013-1777 via openalex
- doi:10.1095/biolreprod.113.107714 via openalex
- doi:10.1128/mcb.23.11.3763-3773.2003 via openalex
- doi:10.1128/mcb.23.21.7742-7755.2003 via openalex
- doi:10.1073/pnas.93.22.12626 via openalex
- doi:10.1093/humrep/det265 via openalex
- doi:10.1177/1933719114537721 via openalex
- doi:10.1002/jcb.22606 via openalex
- doi:10.3109/09513590.2012.650768 via openalex
- doi:10.1159/000029983 via openalex
- doi:10.2147/ijwh.s38800 via openalex
- doi:10.1096/fasebj.2.15.2847948 via openalex
- doi:10.1038/modpathol.3800283 via openalex
- doi:10.1002/(sici)1097-4644(19991215)75:4<640::aid-jcb10>3.0.co;2-8 via openalex
- doi:10.1210/jc.2010-2131 via openalex
- doi:10.1210/rp.57.1.277 via openalex
- doi:10.1002/(sici)1097-4644(19970901)66:3<413::aid-jcb13>3.0.co;2-f via openalex
- doi:10.1016/1071-5576(94)00053-4 via openalex
- doi:10.1016/j.jsgi.2005.04.008 via openalex
Cited by (12)
- Narrative Review of Chronic Inflammation in Uterine Myoma: Lack of Specialized Pro-Resolving Lipid Mediators (SPMs) and Vitamin D as a Potential Reason for the Development of Uterine Fibroids 2025
- Narrative Review of Chronic Inflammation in Uterine Myoma: Lack of Specialized Pro-Resolving Lipid Mediators (SPMs) and Vitamin D as a Potential Reason for the Development of Uterine Fibroids 2025
- The Potential of Vitamin D and Epigallocatechin Gallate (EGCG) for the Treatment of Uterine Fibroids: Evidence From In Vitro to Clinical Studies 2025
- Effect of active vitamin D on proliferation, cell cycle and apoptosis in endometriotic stromal cells 2022
- The association between vitamin D and uterine fibroids: A mendelian randomization study 2022
- Vitamin D and uterine fibroid growth, incidence, and loss: a prospective ultrasound study 2022
- Nutrition in Gynecological Diseases: Current Perspectives 2021
- Herbal Medicine in Uterine Fibroid 2020
- The effect of vitamin D supplementation on the size of uterine leiomyoma in women with vitamin D deficiency. 2019
- Diet-induced vitamin D deficiency triggers inflammation and DNA damage profile in murine myometrium 2018
- Biological role and therapeutic potential of phytoflavonoids and vitamin D in the treatment of patients with uterine myoma, as well as other promising pharmacological directions 2018
- Vitamin D and benign gynaecological diseases: a critical analysis of the current evidence 2015
Source provenance
- openalex
- last seen: 2026-05-11T06:16:32.963054+00:00
License: CC0
· commercial use OK